Although oncogenic KRAS has long been considered to be constitutively active, and thus independent of upstream signals, a requirement for ADAM17 and ERBB1/EGFR in KRAS-induced pancreatic cancer has challenged this idea (Ardito et al., 2012; Navas et al., 2012). This evidence concerns the gene KRAS and pancreatic neoplasm.